# BESPOKE CRC

Source: https://onco.cc/trials/bespoke-crc/  
OnCo record `bespoke-crc` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Natera's US study in which 1,788 people with bowel cancer had Signatera blood tests after surgery and their doctors could act on the result; it records what changed and what happened, but does not randomise anyone.

## Summary

BESPOKE CRC is Natera's prospective observational study of Signatera in resected colorectal cancer. The registry lists 1,788 participants, a start date of 24 April 2020 and a completion date of September 2025, with the overall status not updated. Because doctors chose treatment knowing the result, it can show how often a ctDNA result changes management and how ctDNA-positive and ctDNA-negative patients fare, but not whether acting on the test improves survival; that question belongs to DYNAMIC, CIRCULATE-US and VEGA.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-21
- Also known as: BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer
- Tags: ctdna-roadmap
- Registry id: NCT04264702
- Phase: observational
- Setting: Stage II to IV colorectal cancer after surgery in the United States: Signatera results returned to treating doctors, with treatment decisions and outcomes recorded
- Sponsor: Natera, Inc.
- Enrolled: 1788

## Sources

- ClinicalTrials.gov NCT04264702: https://clinicaltrials.gov/study/NCT04264702

## Connected records

- trials: [CIRCULATE-US](https://onco.cc/trials/circulate-us/)
- roadmaps: [ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment](https://onco.cc/roadmaps/ctdna-tests/)
- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/)
- drugs: [Signatera](https://onco.cc/drugs/signatera/)
- companies: [Natera](https://onco.cc/companies/natera/)
- terms: [Circulating tumour DNA (ctDNA)](https://onco.cc/terms/ctdna/), [Minimal / molecular residual disease (MRD)](https://onco.cc/terms/mrd/), [Tumour-informed versus tumour-naive ctDNA assays](https://onco.cc/terms/tumour-informed-assay/)

---
JSON: https://onco.cc/api/v1/entities/bespoke-crc.json